rs730881919
Variant summary
Our verdict is Likely pathogenic. The variant received 9 ACMG points: 9P and 0B. PVS1PM2_Supporting
This summary comes from the ClinGen Evidence Repository: The c.241G>T (p.Glu81Ter) (NM_000535.7) variant in PMS2 is a nonsense variant predicted to cause a premature stop codon in exon 3 in a gene in which loss-of-function is an established disease mechanism (PVS1). This variant is extremely rare (1 in 1594104 alleles) in gnomAD v4.1 (PM2_Supporting).In summary, this variant meets the criteria to be classified as likely pathogenic for Lynch-Syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen InSiGHT Hereditary Colorectal Cancer/ Polyposis VCEP: PVS1, PM2_SUP (VCEP specifications version 1) LINK:https://erepo.genome.network/evrepo/ui/classification/CA366744765/MONDO:0007356/139
Frequency
Consequence
NM_000535.7 stop_gained
Scores
Clinical Significance
Conservation
Publications
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- Lynch syndrome 4Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- mismatch repair cancer syndrome 4Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae)
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- ovarian cancerInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- Muir-Torre syndromeInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- breast cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- prostate cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 9 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.00000399 AC: 1AN: 250820 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.00000139 AC: 2AN: 1441888Hom.: 0 Cov.: 27 AF XY: 0.00 AC XY: 0AN XY: 718704 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome 4 Pathogenic:4
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
- -
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
The PMS2 c.241G>T (p.Glu81Ter) nonsense variant results in the loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. This variant has been identified in an individual with colorectal cancer, whose tumor cells also lacked PMS2 protein expression (PMID: 27589204). Additionally, the p.Glu81Ter variant was reported in a compound heterozygous state in two individuals with constitutional mismatch repair deficiency and a family history of cancer (PMID: 36647049). This variant is not observed at a significant frequency in version 2.1.1 or version 3.1.2 of the Genome Aggregation Database. Based on the available evidence, the c.241G>T (p.Glu81Ter) variant is classified as pathogenic for Lynch syndrome. -
not provided Pathogenic:2
Observed in an individual with a personal history consistent with pathogenic variants in this gene (PMID: 27589204); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; This variant is associated with the following publications: (PMID: 36988593, 21376568, 24362816, 29922827, 27589204, 36647049) -
The PMS2 c.241G>T (p.Glu81*) variant causes the premature termination of PMS2 protein synthesis. This variant has been reported in the published literature in individuals affected with colorectal cancer (PMID: 27589204 (2016)) and CMMRD (PMID: 36647049 (2023)). The frequency of this variant in the general population, 0.000004 (1/250820 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is consistent with pathogenicity. Based on the available information, this variant is classified as pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:2
The c.241G>T (p.E81*) alteration, located in exon 3 (coding exon 3) of the PMS2 gene, consists of a G to T substitution at nucleotide position 241. This changes the amino acid from a glutamic acid (E) to a stop codon at amino acid position 81. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay Based on data from gnomAD, the T allele has an overall frequency of <0.001% (1/250820) total alleles studied. The highest observed frequency was 0.003% (1/34578) of Latino alleles. This mutation has been identified in a Japanese colorectal cancer cohort (Sugano, 2016). Based on the available evidence, this alteration is classified as pathogenic. -
This variant changes 1 nucleotide in exon 3 of the PMS2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been observed in an individual affected with colorectal cancer demonstrating high microsatellite instability (PMID: 27589204). This variant has also been reported in the compound heterozygous state in two unrelated individuals affected with constitutional mismatch repair deficiency (PMID: 36647049). This variant has been identified in 1/250820 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of PMS2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Hereditary nonpolyposis colon cancer Pathogenic:1
Variant summary: PMS2 c.241G>T (p.Glu81X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4e-06 in 250820 control chromosomes, however due to the PMS2 pseudogene these results should be interpreted with caution (gnomAD). c.241G>T has been reported in the literature in an individual affected with colorectal cancer with a MSI-H tumor lacking PMS2 expression by IHC, and in the compound heterozygous state in two unrelated individuals affected with constitutional mismatch repair deficiency (CMMRD) wherein glioblastoma was the initial CMMRD-associated malignancy and the variant was confirmed to be in trans with large PMS2 deletions (Sugano_2016, Onishi_2023). These data indicate that the variant is very likely associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as either pathogenic (n=4) or likely pathogenic (n=2). Based on the evidence outlined above, the variant was classified as pathogenic. -
Lynch syndrome 1 Pathogenic:1
This sequence change is nonsense variant introducing Premature Termination Codon. This variant has been detected in patients who developed MSI-H glioblastoma at age 10 or younger, along with another variant, PMS2(NM_000535.7): c.2276-125_2445+1584del (exon 14 deletion, phase unknown).It has also been detected in patients under 20 years of age with PMS2-deficient glioblastoma and colorectal adenocarcinoma in IHC, along with another variant, NC_000007.13: g.5876369_612205del (large deletions including PMS2 gene, located in trans). These two patients are considered constitutional mismatch repair deficiency (CMMRD). -
Gastric cancer Pathogenic:1
- -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Glu81*) in the PMS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PMS2 are known to be pathogenic (PMID: 21376568, 24362816). This variant is present in population databases (no rsID available, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with colorectal cancer (PMID: 27589204). ClinVar contains an entry for this variant (Variation ID: 439243). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at